Article
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
The Lancet. Oncology - 1 Mar 2020
Dummer Reinhard, Brase Jan C, Garrett James, Campbell Catarina D, Gasal Eduard, Squires Matthew, Gusenleitner Daniel, Santinami Mario, Atkinson Victoria, Mandalà Mario, Chiarion-Sileni Vanna, Flaherty Keith, Larkin James, Robert Caroline, Kefford Richard, Kirkwood John M, Hauschild Axel, Schadendorf Dirk, Long Georgina V
Abstract excerpt
BACKGROUND: Adjuvant dabrafenib plus trametinib reduced the risk of relapse versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma in the phase 3 COMBI-AD trial. This prespecified exploratory biomarker analysis aimed to evaluate potential prognostic or predictive factors and mechanisms of resistance to adjuvant targeted therapy. METHODS: COMBI-AD is a randomised, double-blind,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.